QCG
RIGL icon

Quadrant Capital Group’s Rigel Pharmaceuticals RIGL Stock Holding History

Quadrant Capital Group’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-626
Closed -$19K – 2695
2022
Q1 		$19K Buy
+626
New +$16.9K ﹤0.01% 1364

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Quadrant Capital Group's RIGL Position: Q2 2022 in Review

Quadrant Capital Group sold out of Rigel Pharmaceuticals (RIGL) in Q2 2022, closing a stake of 626 shares — an estimated $19K sold.

Quadrant Capital Group first reported a position in RIGL in Q1 2022 and held it in 1 quarter. The position peaked at $19K in Q1 2022. 135 funds tracked by Wall St. Rank hold RIGL as of Q2 2022.

  • Quadrant Capital Group reported no remaining Rigel Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Quadrant Capital Group sold 626 Rigel Pharmaceuticals shares in Q2 2022, an estimated $19K.
  • Quadrant Capital Group first reported a position in Rigel Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Quadrant Capital Group's Rigel Pharmaceuticals position peaked at $19K in Q1 2022.
  • 135 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2022.

Based on Quadrant Capital Group's 13F filing for Q2 2022, filed 9 Aug 2022.